Stilla Tech and Atila BioSystems Co-Develop Digital PCR Kits for Oncology
Stilla Technologies and Atila BioSystems agreed to market digital PCR kits and assays produced by Atila for use on Stilla’s naica system.
Read MorePosted by Andy Lundin | Apr 4, 2023 | Cancer |
Stilla Technologies and Atila BioSystems agreed to market digital PCR kits and assays produced by Atila for use on Stilla’s naica system.
Read MorePosted by Andy Lundin | Mar 27, 2023 | Cancer |
SEngine has been certified through the NY State Department of Health’s CLEP program to perform the PARIS Test on samples from the state.
Read MorePosted by Andy Lundin | Mar 22, 2023 | Cancer |
A co-location model for cancer diagnostic services reported a reduction in the time it took to diagnose cancer at a community health center.
Read MorePosted by Andy Lundin | Mar 9, 2023 | Lung Cancer |
The FDA approved the VENTANA PD-L1 (SP263) Assay as a CDx to identify NSCLC patients eligible for treatment with Libtayo (cemiplimab).
Read MorePosted by Andy Lundin | Mar 9, 2023 | Leukemia |
Research shows benefits of screening patients in remission from acute myeloid leukemia for residual disease prior to a bone marrow transplant.
Read More